Exhibit 10.13

 

CONFIDENTIAL

 

Execution Version

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

DATE: OCTOBER 26, 2015

 

 

NOVATION AGREEMENT

 

Among

ALMIRALL, S.A.

ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD.

IRONWOOD PHARMACEUTICALS, INC.

 

 

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

THIS NOVATION AGREEMENT (the “Agreement”) is made on the 26th day of
October 2015

 

BETWEEN:

 

(1)                                          ALMIRALL, S.A., a Spanish company,
whose registered office is at Ronda General Mitre, 151, 08022 Barcelona, Spain
(the “Transferor”);

 

(2)                                          IRONWOOD PHARMACEUTICALS, INC., a
Delaware company, whose registered office is at 301 Binney Street, Cambridge, MA
02142 USA (the “Licensor”); and

 

(3)                                          ALLERGAN PHARMACEUTICALS
INTERNATIONAL LTD., a company registered in Ireland, whose registered office is
at Clonshaugh Business & Technology Park, Coolock, Dublin, D17 E400, Ireland
(the “Transferee”)

 

(together the “Parties” and each a “Party”).

 

RECITALS

 

(A)                                        The Transferor and the Licensor are
parties to the Transferred Contracts (defined below).

 

(B)                                        The Transferor and the Transferee are
parties to the Main Agreement (defined below).

 

(C)                                        Each of the Parties is willing to
agree that the Transferee will assume certain of the Transferor’s liabilities
and obligations, and enjoy certain of the Transferor’s rights and benefits,
under the Transferred Contracts in place of and to the exclusion of the
Transferor, in each case, as of the Effective Time and on the other terms set
forth in and subject to this Agreement.

 

IT IS AGREED as follows:

 

1.                                               INTERPRETATION

 

1.1                                        Capitalized terms used but not
defined in this Agreement shall have the meaning given to them in the License
Agreement. In this Agreement, including the recitals, the following words and
expressions shall have the following meanings:

 

“Effective Time” means the date of this Agreement first above written.

 

“Liabilities and Obligations” means all liabilities and obligations (and all
claims arising from them) whatsoever, whenever and howsoever arising in
connection with the performance or non-performance of a Transferred Contract or
Retained Contract, as applicable, including all indemnification obligations
pursuant to a Transferred Contract or Retained Contract, as applicable (in each
case whether known or unknown, performed or unperformed, discharged or
undischarged, actual, accrued, future, contingent, or prospective, and whether
arising in contract, tort or otherwise).

 

“License Agreement” means the License Agreement dated April 30, 2009 between the
Transferor and the Licensor regarding the Product and Licensed Compound, as
amended or supplemented by (a) [**], (b) [**], (c) [**], (d) [**], (e) an
Amendment dated June 11, 2013 between the Transferor and the Licensor, (f) [**],
(g) [**] and (h) an Amendment dated February 26, 2014 between the Transferor and
the Licensor.

 

1

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

“Main Agreement” means that certain Agreement relating to Linaclotide between
the Transferor and the Transferee dated as of October 26, 2015 pursuant to which
Transferor and Transferee have agreed to transfer substantially all rights
relating to Linaclotide from Transferor to Transferee, including the Transferred
Contracts as set forth in this Agreement.

 

“Manufacturing and Supply Agreement” means the Manufacturing and Supply
Agreement dated April 13, 2010 between the Transferor and the Licensor, as
amended by an Amendment dated July 1, 2013 between the Transferor and the
Licensor.

 

“Pharmacovigilance Agreement” means the Pharmacovigilance Agreement dated
September 30, 2010 between the Transferor and the Licensor, as amended and
restated by the Amended and Restated Pharmacovigilance Agreement dated June 11,
2014 between the Transferor and the Licensor.

 

“Quality Agreements” means (a) the Quality Agreement dated August 7, 2009
between the Transferor and the Licensor, and (b) the Quality Agreement dated
May 7, 2014 between the Transferor and the Licensor.

 

“Retained Contracts” means [**].

 

“Rights” means all rights and benefits (and all claims arising from them)
whatsoever, whenever and howsoever arising in connection with the performance or
non-performance of a Transferred Contract or Retained Contract, as applicable,
including all indemnification rights pursuant to a Transferred Contract or
Retained Contract, as applicable (in each case whether known or unknown, actual,
accrued, future, contingent or prospective, and whether arising in contract,
tort or otherwise).

 

“[**]” means [**].

 

“Transferred Contracts” means each of (a) the License Agreement [**].  For the
avoidance of doubt, the Transferred Contracts will not include any Retained
Contract.

 

1.2                                        Headings are used in this Agreement
for convenience only and shall not affect its interpretation.

 

1.3                                        In this Agreement, unless otherwise
stated or the context otherwise requires, references to clauses, sub-clauses and
schedules are, respectively, to clauses, sub-clauses and schedules in or to this
Agreement.

 

1.4                                        Unless the context otherwise
requires, words denoting the singular shall include the plural and vice versa
and references to any gender shall include all other genders.  References to any
person include bodies corporate, unincorporated associations, partnerships,
governments, governmental agencies and departments, statutory bodies or other
entities, in each case whether or not having a separate legal personality.

 

1.5                                        In this Agreement, unless otherwise
stated or the context otherwise requires, references to the word “including”
will be construed as “including without limitation.”

 

2.                                               NOVATION OF TRANSFERRED
CONTRACTS

 

2.1                                        With effect on and after the
Effective Time:

 

2

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

2.1.1                              the Licensor shall release the Transferor
from the observance, performance and discharge of the Liabilities and
Obligations arising from performance or non-performance of the Transferred
Contracts by or on behalf of Transferee on and after the Effective Time (the
“Post-Effective Time Liabilities and Obligations”);

 

2.1.2                              the Transferee shall be entitled to the
Rights arising from the Transferred Contracts on and after the Effective Time
that would have been Rights of Transferor in the absence of this Agreement (the
“Post-Effective Time Rights”) and in place of and to the exclusion of the
Transferor;

 

2.1.3                              the Transferee undertakes and covenants as a
separate obligation with each of the Transferor and the Licensor to assume,
observe, perform, discharge and be bound by the Post-Effective Time Liabilities
and Obligations arising from the performance or non-performance of the
Transferred Contracts in place of and to the exclusion of the Transferor;

 

2.1.4                              each of the Licensor and the Transferor
accepts the observance, performance and discharge of the Post-Effective Time
Liabilities and Obligations arising from the performance or non-performance of
the Transferred Contracts and the acceptance of the Post-Effective Time Rights
by the Transferee in place of and to the exclusion of the Transferor;

 

2.1.5                              each of the Licensor and Transferor hereby
releases the Transferee from the observance, performance and discharge of the
Liabilities and Obligations arising from performance or non-performance of the
Transferred Contracts by or on behalf of Transferor prior to the Effective Time;

 

2.1.6                              Transferor hereby releases Licensor from the
observance, performance and discharge of the Liabilities and Obligations arising
from performance or non-performance of the Transferred Contracts by or on behalf
of Licensor on or after the Effective Time; and

 

2.1.7                              Transferee hereby releases Licensor from the
observance, performance and discharge of the Liabilities and Obligations arising
from performance or non-performance of the Transferred Contracts by or on behalf
of Licensor prior to the Effective Time;

 

and the Transferred Contracts shall be read and construed accordingly. As of and
following the Effective Time, the term “Partner,” “Almirall,” or other defined
terms referencing the Transferor in the Transferred Contracts will be deemed to
refer to the Transferee. For clarity, (a) neither the Licensor nor the
Transferor releases the other Party from the observance, performance or
discharge of the Liabilities and Obligations (i) that arise from performance or
non-performance of the Transferred Contracts by or on behalf of the other Party
prior to the Effective Time, and (ii) that arise from performance or
non-performance of the Retained Contracts by or on behalf of the other Party at
any time, and (b) Licensor and Transferor shall continue to be entitled to the
Rights that arise from (I) the Transferred Contracts prior to the Effective
Time, and (II) the Retained Contracts at any time, in the case of (I) and (II),
to the exclusion of Transferee.  Further, for clarity, Transferee is not
assuming and will not be liable for any Liabilities and Obligations arising from
performance or

 

3

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

non-performance of (x) the Transferred Contracts by or on behalf of Transferor
prior to the Effective Time or (y) the Retained Contracts by or on behalf of the
Transferor or the Licensor at any time.

 

2.2                                        (a) Each of the Licensor and the
Transferee severally undertakes and covenants with the Transferor that it shall
release the Transferor and not make any claim, counterclaim, demand, action or
proceeding (including arbitration) of any nature whatsoever, or seek to enforce
any right or interest, against the Transferor, with respect to the
Post-Effective Time Liabilities and Obligations, and (b) the Transferor
undertakes and covenants with the Licensor that it shall release the Licensor
and not make any claim, counterclaim, demand, action or proceeding (including
arbitration) of any nature whatsoever, or seek to enforce any right or interest,
against the Licensor, with respect to the Liabilities and Obligations arising
from performance or non-performance of the Transferred Contracts and/or the
exploitation of any Right (including to Technology or other intellectual
property) under the Transferred Contracts, in each case, on or after the
Effective Time. Transferor undertakes and covenants with the Transferee that it
shall release the Transferee and not make any claim, counterclaim, demand,
action or proceeding (including arbitration) of any nature whatsoever, or seek
to enforce any right or interest, against the Transferee, with respect to the
Post-Effective Time Liabilities and Obligations.

 

2.3                                        As of the Effective Time, each of the
Transferee and the Licensor makes to the other the representations and
warranties set forth in [**] of the License Agreement (with respect to this
Agreement and each Transferred Contract).  As of the Effective Time, the
Transferee makes to the Licensor the representations and warranties in [**] of
the License Agreement, and the Licensor makes to the Transferee the
representations and warranties in [**] of the License Agreement.  Each of the
Transferee and the Licensor additionally hereby represents, warrants and
covenants to the other that it will comply with Applicable Law in connection
with exercising its rights and complying with its obligations under the
Transferred Contracts from and after the Effective Time.

 

2.4                                        The Licensor and the Transferor each
represents and warrants to the Transferee that the documents attached hereto as
Exhibit A are true, correct and complete copies of the Transferred Contracts.

 

2.5                                        Clauses 2.1 and 2.2 are subject in
all respects to clause 3 below.

 

3.                                               SURVIVAL OF OBLIGATIONS

 

3.1                                        Notwithstanding the provisions of
clause 2:

 

3.1.1                              Subject to the remainder of this clause
3.1.1, the Transferor undertakes to the Licensor, and the Licensor undertakes to
the Transferor, that it shall observe and perform the duties of confidentiality
and non-disclosure it would have owed to the other under the Transferred
Contracts on or after the Effective Time in the absence of this Agreement,
including pursuant to Section 5.1 (Confidentiality) of the License Agreement.
The Transferor and the Licensor may each disclose to the Transferee information
in its possession relating to the subject matter of the Transferred Contracts to
the extent it is reasonably required by the Transferee in order to exercise the
Post-Effective Time Rights or discharge the Post-Effective Time Liabilities and
Obligations assumed by the Transferee under clause 2. Additionally, unless
otherwise agreed to in writing, the Parties

 

4

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

agree to keep confidential the existence and contents of this Agreement;
provided, that the restrictions of this clause 3.1.1 will not prohibit (a) any
Party from making any disclosure that is required by applicable law, rule or
regulation, or the requirements of a national securities exchange or another
similar regulatory body, or (b) the Licensor or Transferee from disclosing the
existence and contents of this Agreement to any Third Party supplier, partner or
licensee of the Licensed Compound or the Product, subject to the restrictions of
Section 5.7 (Communications with other Linaclotide Partners) of the License
Agreement and to confidentiality obligations no less restrictive than those set
forth in Section 5.1 (Confidentiality) of the License Agreement.

 

3.1.2                              [**] of the License Agreement will continue
to apply to [**] for a period of [**].

 

3.1.3                              [**] of the License Agreement will continue
to apply to [**] for a period of [**].

 

3.1.4                              [**] of the License Agreement will continue
to apply to [**] for a period of [**].

 

3.1.5                              [**] of the License Agreement will continue
to apply to [**] so long as the License Agreement remains in effect, and
thereafter in accordance with [**] of the License Agreement.

 

3.1.6                              With respect to any Technology or other
intellectual property which the Transferor licensed rights to Licensor prior to
the Effective Time pursuant to any Transferred Contract, the license of such
rights pursuant to such Transferred Contract will remain in effect with respect
to the Transferor until ownership of such Technology or other intellectual
property (including all rights, title, and interests therein) is transferred to
the Transferee. Without limiting the generality of the foregoing, [**] of the
License Agreement will remain in effect with respect to [**] until [**].

 

3.1.7                              For clarity, payment obligations accrued by
the Transferor under any Transferred Contract prior to the Effective Time will
remain the responsibility of the Transferor, and the Transferor will make such
payments directly to the Licensor in accordance with the Transferred Contracts.
The Transferor will provide to the Licensor a final report required by
Section 4.4 of the License Agreement within 45 days after the end of the
Calendar Quarter during which the Effective Time occurs. For the avoidance of
doubt, the Transferee shall also have an obligation to provide a report with
respect to the period after the Effective Time pursuant to Section 4.4 of the
License Agreement at such time.  Without limiting the generality of the
foregoing, [**] of the License Agreement will remain binding and in effect
between the Transferor and the Licensor with respect to Transferor’s activities
and obligations prior to the Effective Time until [**], and in the case of [**]
of the License Agreement, [**] following the Year in which the Effective Time
occurs.

 

4.                                               GENERAL

 

4.1                                        Each Party, from time to time on
being required to do so by another Party, shall [**] do or procure the doing of
all such acts and/or execute or procure the execution of all such documents in
such form

 

5

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

                                                         as the Party which has
required it may reasonably consider necessary for giving full effect to this
Agreement and securing to that Party the full benefit of the rights, powers and
remedies conferred upon that Party in this Agreement. Without limiting the
generality of the foregoing, the Transferor will (a) transfer to the Transferee
ownership of all Technology and other intellectual property (including all
rights, title, and interests therein) with respect to which the Transferor
licensed rights to the Licensor prior to the Effective Time pursuant to any
Transferred Contract, (b) transfer to the Transferee all Regulatory Submissions,
other regulatory filings and related material relating to the Transferred
Contracts, and (c) transfer to the Transferee ownership of any other asset,
record, and agreement (including all rights, title, and interests therein) held
by the Transferor that is reasonably required for the Transferee to assume,
observe, perform, discharge and be bound by the Post-Effective Time Liabilities
and Obligations, or is otherwise primarily related to the Transferred Contracts.

 

4.2                                        In accordance with Section 10.8 of
the License Agreement, Licensor hereby gives its written consent to Transferee
to subcontract (but, for clarity, not to sublicense) to Transferor obligations
under the License Agreement pursuant to and on the terms set forth in the
Transitional Services Agreement between Transferee and Transferor dated
October 26, 2015 (the “Transitional Services Agreement”) and the Transitional
Toll Manufacturing Agreement between Transferee and Transferor dated October 26,
2015 (the “Transitional Toll Manufacturing Agreement”), true, accurate and
complete copies of which (other than for the redaction of the financial terms)
have been provided to Licensor prior to the Effective Time. To the extent that
the Transferor provides goods or services to, or conducts work on behalf of, the
Transferee pursuant to the Transitional Services Agreement or Transitional Toll
Manufacturing Agreement on or after the Effective Time, and subject to the
rights and obligations of Licensor and Transferee under the Transferred
Contracts with respect thereto:

 

4.2.1                              Transferee shall ensure that the goods or
services provided, or the performance of such work, by Transferor shall be
consistent with the Transferred Contracts;

 

4.2.2                              Transferee shall promptly notify Licensor of
(a) any claim of breach under the Transitional Services Agreement or
Transitional Toll Manufacturing Agreement, (b) the execution of any amendment of
the Transitional Services Agreement or Transitional Toll Manufacturing
Agreement, or the making of any material changes to the services provided
thereunder, whether by amendment or other means (subject to the rights and
obligations of Licensor and Transferee under the Transferred Contracts with
respect thereto, including, for clarity, delegations pursuant to Section 10.8 of
the License Agreement), or (c) any notice of termination of the Transitional
Services Agreement or Transitional Toll Manufacturing Agreement prior to the
expiration thereof;

 

4.2.3                              the Transferee (and not Licensor) shall be
responsible for all of the financial and other obligations for the provision of
such goods or services or the performance of such work by Transferor;

 

6

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

4.2.4                              the subcontracted and delegated obligations
under this clause 4.2 may not be further subcontracted or delegated to any third
party without further compliance with Section 10.8 of the License Agreement with
respect to such subcontracting or delegating;

 

4.2.5                              the Transferee shall remain fully responsible
to Licensor for the performance of those obligations under the Transferred
Contracts which it delegates to Transferor (including the obligations under
Section 3.2.1 and Section 3.2.2 of the License Agreement) and Licensor may
proceed directly against Transferee for any breach of Transferee’s obligations
under the Transferred Contracts that are delegated to Transferor; and

 

4.2.6                              the Transferor will promptly disclose to the
Transferee all Technology and other intellectual property conceived or reduced
to practice by the Transferor during the provision of such goods or services or
the performance of such work, and the Transferor will and hereby does assign to
the Transferee all rights, title, and interests in and to all such Technology
and other intellectual property.

 

4.3                                        Transferor hereby covenants and
agrees it shall not, without Licensor’s prior written consent, [**].

 

4.4                                        (a) Notwithstanding Section 12.5 of
the [**], the [**] shall not, as of the Effective Time, [**], and (b) [**] shall
not, as of the Effective Time, [**].

 

Notwithstanding Section 10.1 of the [**] and Section 15 of each of the [**],
Licensor and Transferor hereby agree that the [**] and [**] shall terminate as
of the Effective Time with no further force and effect; provided that
Section 10.2 of the [**] shall continue to apply.

 

4.5                                        This Agreement may be executed in any
number of counterparts and by the Parties on separate counterparts.  Each
counterpart shall constitute an original of this Agreement but all the
counterparts together shall constitute one and the same Agreement and any Party
may execute this Agreement by signing any one or more of such counterparts. 
Signature pages of this Agreement may be exchanged by email/pdf or other
electronic means without affecting the validity thereof.

 

4.6                                        No variation of this Agreement shall
be binding on any Party unless and to the extent that it is recorded in a
written document executed by that Party.

 

4.7                                        Nothing in this Agreement is intended
to confer on any third party any right to enforce any term of this Agreement.

 

4.8                                        This Agreement, and any
non-contractual rights or obligations arising out of or in connection with it or
its subject matter, shall be governed by and construed in accordance with the
laws of the State of New York, without reference to any rules of conflict of
laws, and the Parties irrevocably agree that any dispute which may arise out of
or in connection with this Agreement or its subject matter shall be resolved
through arbitration in accordance with Sections 10.1.2 and 10.1.3 in the License
Agreement, which for purposes hereof are deemed repeated in this Agreement,
mutatis mutandis.

 

4.9                                        A notice under this Agreement shall
only be effective if it is in writing and delivered personally or sent by
courier (reputable express international courier if overseas).

 

7

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

Notice given under this Agreement shall be (a) in writing and in English, and
(b) sent to the relevant Party for the attention of the contact and to the
address specified below, or such other address, or person as that Party may
notify to the other in accordance with the provisions of this clause 4.9.

 

4.9.1                              The addresses for service of notices and
communications are:

 

(a)

Transferor:

Almirall, S.A.

 

 

Ronda General Mitre, 151

 

 

08022 Barcelona

 

 

Spain

 

 

Attention: Head Legal Department

 

 

 

(b)

Transferee:

Allergan Pharmaceuticals International Ltd.

 

 

Clonshaugh Business & Technology Park

 

 

Coolock

 

 

Dublin, D17 E400

 

 

Ireland

 

 

Attention: Managing Director

 

 

 

 

With a copy to:

Allergan plc

 

 

Morris Corporate Center III

 

 

400 Interpace Parkway

 

 

Parsippany, NJ 07054

 

 

United States

 

 

Attention: Chief Legal Officer

 

 

 

(c)

Licensor:

Ironwood Pharmaceuticals, Inc.

 

 

301 Binney Street

 

 

Cambridge, MA 02142

 

 

United States

 

 

Attention: Chief Legal Officer

 

 

 

 

With a copy to:

Ropes & Gray LLP

 

 

800 Boylston Street

 

 

Boston, MA 02199

 

 

United States

 

 

Attention: Marc A. Rubenstein

 

A Party may change its details for service of notices as specified in this
clause 4.9 by giving notice in writing to the other Parties in accordance with
this clause 4.9.

 

This clause 4.9 does not apply to the service of any proceedings or other
documents in any legal action or proceedings.

 

4.10                                 Each Party shall pay its own costs and
expenses incurred in connection with the negotiation, preparation, execution and
implementation of this Agreement.

 

8

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

4.11                                 This Agreement (together with the
Transferred Contracts), embodies all of the understandings and obligations
between the Parties concerning the subject matter hereof, and supersedes,
replaces and cancels any and all prior arrangements, agreements or
understandings, whether oral or written, between the Parties with respect to the
subject matter hereof.  For clarity, the Retained Contracts shall not be
superseded, replaced or canceled by the foregoing sentenced.

 

[Balance of Page is Intentionally Blank - Signature Page Follows]

 

9

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

IN WITNESS of which the parties have executed this Agreement on the dates set
forth.

 

 

ALMIRALL, S.A.

ALLERGAN PHARMACEUTICALS
INTERNATIONAL LTD.

 

 

 

 

By:

/s/ Eduardo Sanchiz

 

By:

/s/ Alex Nesbitt

Name:

Eduardo Sanchiz

Name:

Alex Nesbitt

Title:

Chief Executive Officer

Title:

Director

Date:

 

Date:

 

 

 

 

 

IRONWOOD PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ Thomas Graney

 

 

Name:

T. Graney

 

Title:

CFO

 

Date:

 

 

 

[Novation Agreement Signature Page]

 

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

 

EXHIBIT A

 

Transferred Contracts

 

(See attached.)

 

--------------------------------------------------------------------------------

 

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request.  An unredacted version of this exhibit has been filed
separately with the Commission.

 

EXHIBIT A

 

TRANSFERRED CONTRACTS

 

License Agreement:

 

1.              License Agreement dated April 30, 2009 between the Transferor
and the Licensor regarding the Product and Licensed Compound

 

2.              [**]

 

3.              [**]

 

4.              [**]

 

5.              [**]

 

6.              [**]

 

7.              [**]

 

8.              Amendment to the License Agreement dated June 11, 2013 between
the Transferor and the Licensor

 

9.              [**]

 

10.       [**]

 

11.       Amendment to the License Agreement dated February 26, 2014 between the
Transferor and the Licensor

 

[**]

 

12.       [**]

 

13.       [**]

 

--------------------------------------------------------------------------------